Abstract
In metastatic castration-resistant prostate cancer (mCRPC) clinical trials, the assessment of treatment efficacy essentially relies on the time to death and the kinetics of prostate-specific antigen (PSA). Joint modeling has been increasingly used to characterize the relationship between a time to event and a biomarker kinetics, but numerical difficulties often limit this approach to linear models. Here, we evaluated by simulation the capability of a new feature of the Stochastic Approximation Expectation-Maximization algorithm in Monolix to estimate the parameters of a joint model where PSA kinetics was defined by a mechanistic nonlinear mixed-effect model. The design of the study and the parameter values were inspired from one arm of a clinical trial. Increasingly high levels of association between PSA and survival were considered, and results were compared with those found using two simplified alternatives to joint model, a two-stage and a joint sequential model. We found that joint model allowed for a precise estimation of all longitudinal and survival parameters. In particular, the effect of PSA kinetics on survival could be precisely estimated, regardless of the strength of the association. In contrast, both simplified approaches led to bias on longitudinal parameters, and two-stage model systematically underestimated the effect of PSA kinetics on survival. In summary, we showed that joint model can be used to characterize the relationship between a nonlinear kinetics and survival. This opens the way for the use of more complex and physiological models to improve treatment evaluation and prediction in oncology.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase [Internet]. Lyon, France: International Agency for Research on Cancer. 2013. Report No.: 11. Available from: http://globocan.iarc.fr.
Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, et al. SEER Cancer Statistics Review, 1975–2011 [Internet]. National Cancer Institute. 2013. Available from: http://seer.cancer.gov/csr/1975_2011/.
Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 2013;14:760–8.
Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MHA, Lara PN, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99–16. J Natl Cancer Inst. 2006;98:516–21.
Proust-Lima C, Taylor JMG, Williams SG, Ankerst DP, Liu N, Kestin LL, et al. Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts. Int J Radiat Oncol Biol Phys. 2008;72:782–91.
Murawska M, Rizopoulos D, Lesaffre E. A two-stage joint model for nonlinear longitudinal response and a time-to-event with application in transplantation studies. J Probab Stat [Internet]. 2012 [cited 2014 Apr 23];2012. Available from: http://www.hindawi.com/journals/jps/2012/194194/abs/.
Wu L, Liu W, Yi GY, Huang Y. Analysis of longitudinal and survival data: joint modeling, inference methods, and issues. J Probab Stat [Internet]. 2011 [cited 2013 Jul 10];2012. Available from: http://www.hindawi.com/journals/jps/2012/640153/abs/.
Sweeting MJ, Thompson SG. Joint modelling of longitudinal and time-to-event data with application to predicting abdominal aortic aneurysm growth and rupture. Biom J. 2011;53:750–63.
Ibrahim JG, Chu H, Chen LM. Basic concepts and methods for joint models of longitudinal and survival data. J Clin Oncol. 2010;28:2796–801.
Taylor JM, Wang Y. Surrogate markers and joint models for longitudinal and survival data. Control Clin Trials. 2002;23:626–34.
Wulfsohn MS, Tsiatis AA. A joint model for survival and longitudinal data measured with error. Biometrics. 1997;53:330.
Tsiatis AA, Davidian M. Joint modeling of longitudinal and time-to-event data: an overview. Stat Sin. 2004;14:809–34.
Hsieh F, Tseng Y-K, Wang J-L. Joint modeling of survival and longitudinal data: likelihood approach revisited. Biometrics. 2006;62:1037–43.
Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn. 2003;30:387–404.
Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics. 2000;1:465–80.
Rizopoulos D. Joint models for longitudinal and time-to-event data: with applications in R. CRC Press. 2012. p. 275
Hu C, Sale ME. A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn. 2003;30:83–103.
Björnsson MA, Friberg LE, Simonsson USH. Performance of nonlinear mixed effects models in the presence of informative dropout. AAPS J. 2014;17:245–55.
Vigan M, Stirnemann J, Mentré F. Evaluation of estimation methods and power of tests of discrete covariates in repeated time-to-event parametric models: application to Gaucher patients treated by imiglucerase. AAPS J. 2014;16:415–23.
Mbogning C, Bleakley K, Lavielle M. Joint modelling of longitudinal and repeated time-to-event data using nonlinear mixed-effects models and the stochastic approximation expectation–maximization algorithm. J Stat Comput Simul. 2015;85:1512–28.
Tu H, Jacobs SC, Borkowski A, Kyprianou N. Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-β1 and bcl-2 expression. Int J Cancer. 1996;69:357–63.
Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery—what we have learned and where we are going. J Urol. 1999;162:293–306.
Rizopoulos D, Verbeke G, Lesaffre E. Fully exponential Laplace approximations for the joint modelling of survival and longitudinal data. J R Stat Soc Ser B Stat Methodol. 2009;71:637–54.
R Development Core Team. R Development Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org. R Foundation for statistical computing, Vienna, Austria.
Taylor JMG, Yu M, Sandler HM. Individualized predictions of disease progression following radiation therapy for prostate cancer. J Clin Oncol. 2005;23:816–25.
Ribba B, Holford N, Mentré F. The use of model-based tumor-size metrics to predict survival. Clin Pharmacol Ther. 2014;96:133–5.
Yu M, Law NJ, Taylor JMG, Sandler HM. Joint longitudinal survival cure models and their application to prostate cancer. Stat Sin. 2004;14:835–62.
Ribba B, Holford NH, Magni P, Trocóniz I, Gueorguieva I, Girard P, et al. A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis. CPT Pharmacomet Syst Pharmacol. 2014;3:e113.
Acknowledgments
The authors would like to thank Drug Disposition Department, Sanofi, Paris which supported Solène Desmée by a research grant during this work. They also thank Hervé Le Nagard for the use of the computer cluster services hosted on the “Centre de Biomodélisation UMR1137”.
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
ESM 1
(DOCX 91 kb)
Rights and permissions
About this article
Cite this article
Desmée, S., Mentré, F., Veyrat-Follet, C. et al. Nonlinear Mixed-Effect Models for Prostate-Specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: a Comparison by Simulation of Two-Stage and Joint Approaches. AAPS J 17, 691–699 (2015). https://doi.org/10.1208/s12248-015-9745-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-015-9745-5